Acting Director, UW Medicine, Neuropathology
Adjunct Professor, Neurology & Ophthalmology
Adjunct Professor, Oral Health Sciences
Office: HMC, Room NJB-1450
Parkinson’s disease (PD), the most common serious movement disorder afflicting millions of Americans, is diagnosed when patients present with cardinal parkinsonian signs (bradykinesia, rigidity, tremor, and postural instability as depicted in the diagram on the left) and show a favorable responsiveness to levodopa or dopamine (DA) agonists.
Pathological hallmarks of PD are loss of dopaminergic neurons in the substantia nigra (SN) with resultant depletion of DA and the presence of Lewy bodies in the remaining neurons (indicated by an arrow in the photo micrograph). Despite decades of extensive research, there is currently still no cure for the disease, largely because its pathogenesis has not been fully understood yet. In addition, there are quite a few other movement disorders that mimic PD clinically including response to levodopa and DA agonists, making an accurate diagnosis of PD difficult sometimes even in the best hands. Finally, the natural course of PD varies substantially, with most patients developing first mild cognitive impairment (MCI) and then dementia as the disease progresses.
1) understand the molecular mechanisms of Parkinson’s disease development
2) understand the molecular mechanisms of Parkinson’s disease progression
3) explore unique biomarkers for diagnosing Parkinson’s disease and monitoring its progression
- Montine, T. Shi, M, .and Zhang J (2010). Reduction in CSF amyloid b42 without a corresponding increase in tau species is commonly found in patients with Parkinson’s disease and cognitive impairment or dementia. Mov Disord In press (2010).
- Mata, I., Zhang, j and Zabeitian C, A SNCA Variant Associated with Parkinson’s Disease and Plasma α-Synuclein Level. Arch Neurol In press (2010).
- Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, and Zhang J (2010). Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett. 480:78–82, 2010.
- Liu J, Shi M, Hong Z, Zhang J, Bradner J, Quinn T, Beyer RP, Mcgeer PL, Chen S, and Zhang J(2010). Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein. Proteomics. 10(11):2138-50, 2010.
- Rostomily RC, Born DE, Beyer RP, Jin J, Alvord EC Jr, Mikheev, AM, Matthews RT, Pan C, Khorasani L, Sonnen JA, Montine TJ, Shi M, and Zhang J (2010). Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J Proteome Res. 7;9(5):2610-8, 2010.
- Caudle WM, Bammler TK, Lin Y, Pan S, and Zhang J (2010). Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother, 10(6):925-42, 2010.
- Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, and Zhang J(2010). DJ-1 and synuclein as biomarkers of Parkinson’s disease, Brain, 133:713-26, 2010.
- Oh JH, Pan S, Zhang J, Gao J, MSQ: A tool for quantification of proteomics data generated by LC-MALDI TOF/TOF based targeted quantitative proteomics platform. Rapid Comm Mass Spec, 24(4):403-8, 2010.
- Hwang H, Zhang JP, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, Nutt J, Albin R, Gearing M, Beyer RP, Shi M, and Zhang J (2010). Glycoproteomics in Neurodegenerative Diseases. Mass Spec Reviews, 29(1):79-125.
- Caudle WM, Zhang J (2009). Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol. 220:230-3, 2009.
- Shi M, Bradner J, Bammler TK, Eaton DL, Zhang JP, Ye ZC, Wilson AM, Montine TJ, Pan C andZhang J (2009). Identification of synaptosomal glutathione S-transferase Pi as a key protein in Parkinson disease progression, Am J Pathol. 2009 Jun 4.
- Caudle WM, Kitsou E, Li J, Bradner J, Zhang J (2009). A role for a novel protein, nucleolin, in Parkinson’s disease, Neurosci Lett. 2009 Jul 31;459(1):11-5. Epub 2009 May 4.
- Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, Zhang J (2009). Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 4;29(5):1480-5.
- Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, Zhang J, Brentnall TA (2009), Mass spectrometry based targeted protein quantification: methods and applications, J. Proteome Res. 6;8(2):787-797.